J&J Considers Sale of Anti-Dandruff Shampoo Nizoral

Johnson & Johnson is considering a sale of its anti-dandruff shampoo Nizoral as the U.S. health-care giant continues to streamline its portfolio of products, according to people familiar with the matter.

A sale of Nizoral could be valued at a few hundred million dollars and attract other health-care and consumer companies with an interest in over-the-counter treatments, the people said, asking not to be identified because the deliberations are private. J&J is working with financial advisers on the sale, which is at a preliminary stage, the people said.